Riskpilot← Back to searchSign inGet full accessCureLink AB
ABActiveOrg 5592170194Esplanaden 15 BTemporary employment agency activities and other human resource provisions · NACE 7820Est. 20196 employees
Revenue 2025
SEK 45,1M
+32% vs 2024
EBITDA margin
2.0%
+21% vs 2024
Equity ratio
25.0%
Financial strength
Net profit 2025
SEK 710K
+21% vs 2024
| Revenue | SEK 45,1M | +32% |
| EBITDA | SEK 901K | +21% |
| Net profit | SEK 710K | +21% |
| Total assets | SEK 7,6M | -13% |
| Equity | SEK 1,9M | +12% |
| Employees | 6 | — |
Legal name
CureLink AB
Org number
5592170194
Legal form
Aktiebolag
NACE code
7820 · Temporary employment agency activities and other human resource provisions
Founded
3 september 2019
Share capital
SEK 50 000
Employees
6 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall bedriva rekrytering och uthyrning av personal inom hälsa-, sjukvård och omsorg. Bolaget skall även kunna äga och förvalta såväl fast som lös egendom samt därmed förenlig verksamhet.
Address
Esplanaden 15 B
Email
tobias.folkesson@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 20 044 | 27 126 | 30 446 | 34 105 | 45 079 |
| Staff expenses | — | — | — | — | −3 017 |
| EBITDA | 1 227 | 1 034 | 1 211 | 745 | 901 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | — |
| EBIT | 1 227 | 1 034 | 1 211 | 745 | 901 |
| Net financials | −2 | −2 | −4 | 8 | 5 |
| Profit before tax | 1 226 | 1 032 | 1 207 | 753 | 906 |
| Tax | −258 | −223 | −260 | −165 | −195 |
| Net profit | 968 | 809 | 947 | 588 | 710 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 4 787 | 5 757 | 6 812 | 8 749 | 7 607 |
| Equity | 1 255 | 1 704 | 1 851 | 1 689 | 1 899 |
| Long-term debt | 400 | 400 | 220 | 220 | 220 |
| Short-term debt | 3 133 | 3 653 | 4 741 | 6 840 | 5 488 |
| Total debt | 3 533 | 4 053 | 4 961 | 7 060 | 5 708 |
EBITDA margin
2.0%
This company
15.8%
Market median
-87% vs market
20212025
Equity ratio
25.0%
This company
38.2%
Market median
-35% vs market
20212025
Return on equity
37.4%
This company
18.4%
Market median
+103% vs market
20212025
Net profit margin
1.6%
This company
8.1%
Market median
-80% vs market
20212025
Asset turnover
5.93×
This company
1.12×
Market median
+429% vs market
20212025
Debt / equity
3.01×
This company
0.62×
Market median
-385% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
MC | Audit | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 51% | 51% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Cross Alley Invest AB
CureLink AB Board members of CureLink AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Magnus Carl-Johan Persson | Audit | 0 companies |
| Carl Johan Tobias Folkesson | Deputy Board Member | 0 companies |
| Stina Adielsson | Board of Directors | 0 companies |